Literature DB >> 10362794

Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption.

E Santoni-Rugiu1, M R Jensen, V M Factor, S S Thorgeirsson.   

Abstract

We have previously shown in transgenic mice that transforming growth factor (TGF)-alpha dramatically enhances c-myc-induced hepatocarcinogenesis by promoting proliferation and survival of hepatocellular carcinoma (HCC) cells. As transgenic livers display increased levels of mature TGF-beta1 from the early stages of hepatocarcinogenesis, we have now assessed whether impairment of TGF-beta1 signaling contributes to the deregulation of cell cycle progression and apoptosis observed during this process. Focal preneoplastic lesions lacking expression of TGF-beta receptor type II (TbetaRII) were detected in c-myc/TGF-alpha but not in c-myc livers. In c-myc/TGF-alpha mice, 40% (2/5) of adenomas and 90% (27/30) of HCCs showed down-regulation of TbetaRII expression in comparison with 11% (2/18) of adenomas and 47% (14/30) of HCCs in c-myc mice. Down-regulation of the TGF-beta1-inducible p15(INK4B) mRNA and reduced apoptotic rates in TbetaRII-negative HCCs further indicated the disruption of TGF-beta1 signaling. Furthermore, both TbetaRII-negative and -positive c-myc TGF-alpha HCCs, but not c-myc HCCs, were characterized by decreased levels of the cell cycle inhibitor p27. These results suggest 1) an inverse correlation of decreased p27 expression with the particularly strong expression of TGF-alpha in these lesions, consistent with the capacity of TGF-alpha signaling to post-transcriptionally regulate p27, and 2) the presence of alternative, downstream defects of TGF-beta1 signaling in c-myc/TGF-alpha HCCs that may impair the growth-inhibitory response to TGF-beta1. Thus, the accelerated neoplastic development in c-myc/TGF-alpha mice is associated with an early and frequent occurrence of TbetaRII-negative lesions and with reduced levels of p27 in HCC cells, indicating that disruption of TGF-beta1 responsiveness may play a crucial role in the enhancement of c-myc-induced hepatocarcinogenesis by TGF-alpha.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362794      PMCID: PMC1866625          DOI: 10.1016/s0002-9440(10)65425-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

2.  Inhibitory effects of transforming growth factor beta 1 on mitogenic response, transforming growth factor alpha, and c-myc in quiescent, well-differentiated colon carcinoma cells.

Authors:  K M Mulder; Q Zhong; H G Choi; L E Humphrey; M G Brattain
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

3.  Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.

Authors:  E Santoni-Rugiu; M R Jensen; S S Thorgeirsson
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

4.  Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.

Authors:  K Polyak; M H Lee; H Erdjument-Bromage; A Koff; J M Roberts; P Tempst; J Massagué
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells.

Authors:  J M Slingerland; L Hengst; C H Pan; D Alexander; M R Stampfer; S I Reed
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

6.  Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis.

Authors:  H Murakami; N D Sanderson; P Nagy; P A Marino; G Merlino; S S Thorgeirsson
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

7.  Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line.

Authors:  A Okamoto; W Jiang; S J Kim; E A Spillare; G D Stoner; I B Weinstein; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

8.  Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA.

Authors:  M Inagaki; A Moustakas; H Y Lin; H F Lodish; B I Carr
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.

Authors:  A Kiss; N J Wang; J P Xie; S S Thorgeirsson
Journal:  Clin Cancer Res       Date:  1997-07       Impact factor: 12.531

10.  p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.

Authors:  G J Hannon; D Beach
Journal:  Nature       Date:  1994-09-15       Impact factor: 49.962

View more
  15 in total

1.  Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway.

Authors:  E Santoni-Rugiu; J Falck; N Mailand; J Bartek; J Lukas
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

2.  Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2.

Authors:  Yu-An Yang; Gen-Mu Zhang; Lionel Feigenbaum; Ying E Zhang
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

Review 3.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

4.  A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment.

Authors:  Galina A Gusarova; I-Ching Wang; Michael L Major; Vladimir V Kalinichenko; Timothy Ackerson; Vladimir Petrovic; Robert H Costa
Journal:  J Clin Invest       Date:  2006-12-14       Impact factor: 14.808

5.  Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model.

Authors:  V M Factor; D Laskowska; M R Jensen; J T Woitach; N C Popescu; S S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

6.  TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer.

Authors:  Ji Yeon Baek; Shelli M Morris; Jean Campbell; Nelson Fausto; Matthew M Yeh; William M Grady
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

7.  Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer.

Authors:  Cédric Coulouarn; Valentina M Factor; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Carcinogenesis       Date:  2011-07-18       Impact factor: 4.944

8.  Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.

Authors:  James M Dolezal; Huabo Wang; Sucheta Kulkarni; Laura Jackson; Jie Lu; Sarangarajan Ranganathan; Eric S Goetzman; Sivakama S Bharathi; Kevin Beezhold; Craig A Byersdorfer; Edward V Prochownik
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

9.  Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis.

Authors:  Tai On Yau; Thomas Ho Yin Leung; Sandra Lam; Oi Fung Cheung; Edmund Kwok Kwan Tung; Pek Lan Khong; Amy Lam; Sookja Chung; Irene Oi Lin Ng
Journal:  PLoS One       Date:  2009-08-10       Impact factor: 3.240

Review 10.  Genetically modified animal models recapitulating molecular events altered in human hepatocarcinogenesis.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.